Loading...
XBRUBCART
Market cap28mUSD
Sep 22, Last price  
0.29EUR
Name

Biocartis Group NV

Chart & Performance

D1W1MN
XBRU:BCART chart
P/E
—
P/S
0.47
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
22.36%
Revenues
57m
+19.08%
3,551,0008,333,0008,477,00013,333,00012,098,00020,957,00027,811,00037,444,00043,128,00048,269,00057,481,000
Net income
-65m
L-8.52%
-44,431,000-35,620,000-9,118,000-39,797,000-49,777,000-41,960,000-48,153,000-64,068,000-62,934,000-71,472,000-65,381,000
CFO
-45m
L-31.74%
-41,262,000-41,179,000-35,884,000-23,357,000-53,312,000-41,405,000-41,993,000-54,254,000-39,267,000-65,716,000-44,855,000

Profile

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.
URL
https://biocartis.com/
IPO date
Apr 27, 2015
Employees
526
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
57,481
19.08%
48,269
11.92%
Cost of revenue
76,765
84,271
Unusual Expense (Income)
NOPBT
(19,284)
(36,002)
NOPBT Margin
Operating Taxes
(240)
(243)
Tax Rate
NOPAT
(19,044)
(35,759)
Net income
(65,381)
-8.52%
(71,472)
13.57%
Dividends
Dividend yield
Proceeds from repurchase of equity
23,055
BB yield
-72.12%
Debt
Debt current
20,597
11,878
Long-term debt
116,406
162,295
Deferred revenue
149
313
Other long-term liabilities
205
75
Net debt
105,900
118,367
Cash flow
Cash from operating activities
(44,855)
(65,716)
CAPEX
(1,937)
(3,755)
Cash from investing activities
(5,431)
(3,748)
Cash from financing activities
22,463
(1,204)
FCF
(15,559)
(39,087)
Balance
Cash
24,925
52,322
Long term investments
6,178
3,484
Excess cash
28,229
53,393
Stockholders' equity
(662,005)
(745,772)
Invested Capital
754,239
866,132
ROIC
ROCE
EV
Common stock shares outstanding
60,546
65,971
Price
0.53
-85.39%
3.62
-22.26%
Market cap
31,969
-86.60%
238,485
-20.97%
EV
137,869
356,852
EBITDA
(8,803)
(26,157)
EV/EBITDA
Interest
11,187
9,320
Interest/NOPBT